A detailed history of Godsey & Gibb Associates transactions in Astrazeneca PLC stock. As of the latest transaction made, Godsey & Gibb Associates holds 49 shares of AZN stock, worth $3,157. This represents 0.0% of its overall portfolio holdings.

Number of Shares
49
Previous 227 78.41%
Holding current value
$3,157
Previous $17,000 82.35%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$76.67 - $87.62 $13,647 - $15,596
-178 Reduced 78.41%
49 $3,000
Q2 2024

Jul 23, 2024

SELL
$66.81 - $80.83 $400 - $484
-6 Reduced 2.58%
227 $17,000
Q1 2024

Apr 23, 2024

SELL
$61.03 - $69.57 $31,857 - $36,315
-522 Reduced 69.14%
233 $15,000
Q3 2023

Oct 25, 2023

SELL
$64.85 - $71.7 $1,945 - $2,151
-30 Reduced 3.82%
755 $51,000
Q1 2023

Apr 18, 2023

SELL
$63.15 - $71.6 $12,630 - $14,319
-200 Reduced 20.3%
785 $54,000
Q4 2022

Jan 18, 2023

SELL
$54.21 - $70.44 $13,444 - $17,469
-248 Reduced 20.11%
985 $0
Q3 2022

Oct 24, 2022

BUY
$53.02 - $135.75 $65,373 - $167,379
1,233 New
1,233 $68,000

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $200B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Godsey & Gibb Associates Portfolio

Follow Godsey & Gibb Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Godsey & Gibb Associates, based on Form 13F filings with the SEC.

News

Stay updated on Godsey & Gibb Associates with notifications on news.